Integrated analysis of microarray data of atherosclerotic plaques: Modulation of the ubiquitin-proteasome system

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Wang, Zhe ^a   Guo, Dong ^b   Yang, Bin ^c   Wang, Jian ^d   Wang, Rong ^a   Wang, Xiaowei ^a   Zhang, Qunye ^a  

^a SHANDONG UNIVERSITY   (China)

^b TAISHAN MEDICAL UNIVERSITY   (China)

^c ZAOZHUANG UNIVERSITY   (China)

^d SHANGHAI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MESSENGER RNA; MICRORNA; PROTEASOME; UBIQUITIN; TRANSCRIPTION FACTOR;

ADULT; AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DNA METHYLATION; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN TISSUE; MALE; PROTEIN ANALYSIS; PROTEIN MICROARRAY; SIGNAL TRANSDUCTION; UBIQUITIN PROTEASOME SYSTEM; UBIQUITINATION; VASCULAR TISSUE; BINDING SITE; BIOLOGY; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETIC ASSOCIATION; GENETICS; GENOMICS; METABOLISM; NUCLEOTIDE MOTIF; PATHOLOGY; POSITION WEIGHT MATRIX; PROCEDURES;

BINDING SITES; CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; DNA METHYLATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HUMANS; MICRORNAS; NUCLEOTIDE MOTIFS; PLAQUE, ATHEROSCLEROTIC; POSITION-SPECIFIC SCORING MATRICES; PROTEASOME ENDOPEPTIDASE COMPLEX; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; UBIQUITIN;

EID: 84908027284     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110288     Document Type: Article

References (49)

1. Anand SS, Yusuf S (2011) Stemming the global tsunami of cardiovascular disease. Lancet 377:529-532.
2. Lusis AJ (2000) Atherosclerosis. Nature 407:233-241.
3. Rader DJ, Daugherty A (2008) Translating molecular discoveries into new therapies for atherosclerosis. Nature 451:904-913.
4. Zeng J, Xiong Y, Li G, Liu M, He T, et al. (2013) MiR-21 is overexpressed in response to high glucose and protects endothelial cells from apoptosis. Exp Clin Endocrinol Diabetes 121:425-430.
5. Sun Y, Chen D, Cao L, Zhang R, Zhou J, et al. (2013) MiR-490-3p modulates the proliferation of vascular smooth muscle cells induced by ox-LDL through targeting PAPP-A. Cardiovasc Res 100:272-279.
6. Gracias DT, Stelekati E, Hope JL, Boesteanu AC, Doering TA, et al. (2013) The microRNA miR-155 controls CD8 (+) T cell responses by regulating interferon signaling. Nat Immunol 14:593-602.
7. Chen T, Huang Z, Wang L, Wang Y, Wu F, et al. (2009) MicroRNA-125a-5p partly regulates the inflammatory response, lipid uptake, and ORP9 expression in oxLDL-stimulated monocyte/macrophages. Cardiovasc Res 83:131-139.
8. Zaina S, Lund G (2013) Atherosclerosis: cell biology and lipoproteins-panoramic views of DNA methylation landscapes of atherosclerosis. Curr Opin Lipidol 24:369-370.
9. Jia L, Zhu L, Wang JZ, Wang XJ, Chen JZ, et al. (2013) Methylation of FOXP3 in regulatory T cells is related to the severity of coronary artery disease. Atherosclerosis 228:346-352.
10. Chen KC, Wang YS, Hu CY, Chang WC, Liao YC, et al. (2011) OxLDL upregulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases. FASEB J 25:1718-1728.
11. Döring Y, Noels H, Weber C (2012) The use of high-throughput technologies to investigate vascular inflammation and atherosclerosis. Arterioscler Thromb Vasc Biol 32:182-195.
12. Civelek M, Manduchi E, Riley RJ, Stoeckert CJ Jr, Davies PF (2011) Coronary artery endothelial transcriptome in vivo: identification of endoplasmic reticulum stress and enhanced reactive oxygen species by gene connectivity network analysis. Circ Cardiovasc Genet 4:243-252.
13. Castillo-Diàz SA, Garay-Sevilla ME, Hernández-González MA, Solís-Martínez MO, Zaina S (2010) Extensive demethylation of normally hypermethylated CpG islands occurs in human atherosclerotic arteries. Int J Mol Med 26:691-700.
14. Eberini I, Wait R, Calabresi L, Sensi C, Miller I, et al. (2013) A proteomic portrait of atherosclerosis. J Proteomics 82:92-112.
15. Zhang QY, Mao JH, Liu P, Huang QH, Lu J, et al. (2009) A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL associated leukemia. Proc Natl Acad Sci U S A 106:3378-3383.
16. Bock C, Tomazou EM, Brinkman AB, Müller F, Simmer F, et al. (2010) Quantitative comparison of genome-wide DNA methylation mapping technologies. Nat Biotechnol 28:1106-1114.
17. Krämer A, Green J, Pollard J Jr, Tugendreich S (2014) Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics 30:523-530.
18. Huang da W, Sherman BT, Lempicki RA (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37:1-13.
19. Li X, Liu H, Qin L, Tamasi J, Bergenstock M, et al. (2007) Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis. J Biol Chem 282:33086-33097.
20. Bader GD, Betel D, Hogue CW (2003) BIND: the Biomolecular Interaction Network Database. Nucleic Acids Res 31:248-250.
21. Xenarios I, Salwínski L, Duan XJ, Higney P, Kim SM, et al. (2002) DIP, the Database of Interacting Proteins: a research tool for studying cellular networks of protein interactions. Nucleic Acids Res 30:303-305.
22. Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, et al. (2009) Human Protein Reference Database-2009 update. Nucleic Acids Res 37:D767-D772.
23. Kerrien S, Aranda B, Breuza L, Bridge A, Broackes-Carter F, et al. (2012) The IntAct molecular interaction database in 2012. Nucleic Acids Res 40:D841-D846.
24. Chatr-Aryamontri A, Breitkreutz BJ, Heinicke S, Boucher L, Winter A, et al. (2013) The BioGRID interaction database: 2013 update. Nucleic Acids Res 41:D816-D823.
25. Alcaraz NM, Kucuk H, Weile J, Wipat A, Baumbach J (2011) Key-PathwayMiner-Detecting case-specific biological pathways by using expression data. Int Math 7:299-313.
26. Huang Z, Bassil CF, Murphy SK (2013) Methylation-specific PCR. Methods Mol Biol 1049:75-82.
27. Wagner JR, Busche S, Ge B, Kwan T, Pastinen T, et al. (2014) The relationship between DNA methylation, genetic and expression inter-individual variation in untransformed human fibroblasts. Genome Biol 15:R37. [Epub ahead of print]
28. Muers M (2013) Gene expression: Disentangling DNA methylation. Nat Rev Genet 14:519.
29. García-Carpizo V, Ruiz-Llorente L, Fraga M, Aranda A (2011) The growing role of gene methylation on endocrine function. J Mol Endocrinol 47:R75-R89.
30. Aran D, Toperoff G, Rosenberg M, Hellman A (2011) Replication timingrelated and gene body-specific methylation of active human genes. Hum Mol Genet 20:670-680.
31. Guilleret I, Yan P, Grange F, Braunschweig R, Bosman FT, et al. (2002) Hypermethylation of the human telomerase catalytic subunit (hTERT) gene correlates with telomerase activity. Int J Cancer 101:335-341.
32. Yu CC, Furukawa M, Kobayashi K, Shikishima C, Cha PC, et al. (2012) Genome-wide DNA methylation and gene expression analyses of monozygotic twins discordant for intelligence levels. PLoS One 7:e47081.
33. Vogel U, Jensen MK, Due KM, Rimm EB, Wallin H, et al. (2011) The NFKB1 ATTG ins/del polymorphism and risk of coronary heart disease in three independent populations. Atherosclerosis 219:200-204.
34. Mercer J, Bennett M (2006) The role of p53 in atherosclerosis. Cell Cycle 5:1907-1909.
35. Ben-Shoshan J, Afek A, Maysel-Auslender S, Barzelay A, Rubinstein A, et al. (2009) HIF-1alpha overexpression and experimental murine atherosclerosis. Arterioscler Thromb Vasc Biol 29:665-670.
36. de Nigris F, Youssef T, Ciafré S, Franconi F, Anania V, et al. (2000) Evidence for oxidative activation of c-Myc-dependent nuclear signaling in human coronary smooth muscle cells and in early lesions of Watanabe heritable hyperlipidemic rabbits: protective effects of vitamin E. Circulation 102:2111-2117.
37. Rayner KJ, Sheedy FJ, Esau CC, Hussain FN, Temel RE, et al. (2011) Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest 121:2921-2931.
38. Hilgendorf I, Eisele S, Remer I, Schmitz J, Zeschky K, et al. (2011) The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 31:1991-1999.
39. Rodríguez I, Coto E, Reguero JR, González P, Andrés V, et al. (2007) Role of the CDKN1A/p21, CDKN1C/p57, and CDKN2A/p16 genes in the risk of atherosclerosis and myocardial infarction. Cell Cycle 6:620-625.
40. Fornari F, Milazzo M, Chieco P, Negrini M, Marasco E, et al. (2012) In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. J Pathol 227:275-285.
41. Martinelli R, Nardelli C, Pilone V, Buonomo T, Liguori R, et al. (2010) miR-519d overexpression is associated with human obesity. Obesity (Silver Spring) 18:2170-2176.
42. Ort T, Voronov S, Guo J, Zawalich K, Froehner SC, et al. (2001) Dephosphorylation of beta2-syntrophin and Ca2+/mu-calpain-mediated cleavage of ICA512 upon stimulation of insulin secretion. EMBO J 20:4013-4023.
43. Herrmann J, Edwards WD, Holmes DR Jr, Shogren KL, Lerman LO, et al. (2002) Increased ubiquitin immunoreactivity in unstable atherosclerotic plaques associated with acute coronary syndromes. J Am Coll Cardiol 40:1919-1927.
44. Versari D, Herrmann J, Gössl M, Mannheim D, Sattler K, et al. (2006) Dysregulation of the ubiquitin-proteasome system in human carotid atherosclerosis. Arterioscler Thromb Vasc Biol 26:2132-2139.
45. Barringhaus KG, Matsumura ME (2007) The proteasome inhibitor lactacystin attenuates growth and migration of vascular smooth muscle cells and limits the response to arterial injury. Exp Clin Cardiol 12:119-124.
46. Feng B, Zhang Y, Mu J, Ye Z, Zeng W, et al. (2010) Preventive effect of a proteasome inhibitor on the formation of accelerated atherosclerosis in rabbits with uremia. J Cardiovasc Pharmacol 55:129-138.
47. Van Herck JL, De Meyer GR, Martinet W, Bult H, Vrints CJ, et al. (2010) Proteasome inhibitor bortezomib promotes a rupture-prone plaque phenotype in ApoE-deficient mice. Basic Res Cardiol 105:39-50.
48. Herrmann J, Saguner AM, Versari D, Peterson TE, Chade A, et al. (2007) Chronic proteasome inhibition contributes to coronary atherosclerosis. Circ Res 101:865-874.
49. Di Filippo C, Marfella R, D'Amico M (2008) Possible dual role of ubiquitinproteasome system in the atherosclerotic plaque progression. J Am Coll Cardiol 52:1350-1351.